Drug Patents owned by Merck Sharp Dohme

1. Drug name - BELSOMRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(7 years from now)

CN101627028B MERCK SHARP DOHME Substituted Trioxepane Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

CN101880276B MERCK SHARP DOHME Substituted Trioxepane Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

CN101880276A MERCK SHARP DOHME Substituted Diazacycloheptane Compound For Use As Orexin Receptor Antagonist
Nov, 2027

(5 years from now)

CN101627028A MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

IN280091B MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

IN200902716P4 MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

EP2392572B1 MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

EP2089382A1 MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

EP2392572A1 MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

EP2089382B1 MERCK SHARP DOHME Substituted Diazepan Compounds As Orexin Receptor Antagonists
Nov, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist May, 2033

(10 years from now)

Drugs and Companies using SUVOREXANT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

2. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820660 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(6 months from now)

US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(11 months from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

CN102229605A MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN1700918A MERCK SHARP DOHME N About The Hiv Integrase-Substituted Hydroxy Pyrimidinone Carboxamide Inhibitors
Oct, 2022

(13 days from now)

CN1700918B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN102219750A MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN102229605B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN102219750B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(13 days from now)

CN101068793B MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

CN101068793A MERCK SHARP DOHME Sylvine Of Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

IN200400868P4 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(13 days from now)

IN212400B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(13 days from now)

EP1441735B1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1441735A1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1819700B1 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819700A2 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819683B1 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819683A2 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(13 days from now)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(13 days from now)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2024

(1 year, 5 months from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor Sep, 2029

(6 years from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

3. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(11 months from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

CN102229605A MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN1700918A MERCK SHARP DOHME N About The Hiv Integrase-Substituted Hydroxy Pyrimidinone Carboxamide Inhibitors
Oct, 2022

(13 days from now)

CN1700918B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN102219750A MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN102229605B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitor Relative To Hiv Integrase
Oct, 2022

(13 days from now)

CN102219750B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(13 days from now)

CN101068793B MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

CN101068793A MERCK SHARP DOHME Sylvine Of Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

IN200400868P4 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(13 days from now)

IN212400B MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Oct, 2022

(13 days from now)

EP1441735B1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1441735A1 MERCK SHARP DOHME N-Substituted Hydroxypyrimidinone Carboxamide Inhibitors Of Hiv Integrase
Jan, 2023

(2 months from now)

EP1819700B1 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819700A2 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819683B1 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

EP1819683A2 MERCK SHARP DOHME Potassium Salt Of An Hiv Integrase Inhibitor
Dec, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(13 days from now)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Oct, 2022

(13 days from now)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2023

(6 months from now)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase Apr, 2024

(1 year, 5 months from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor Sep, 2029

(6 years from now)

US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor Oct, 2030

(8 years from now)

US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor Apr, 2031

(8 years from now)

US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor Mar, 2032

(9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET, CHEWABLE;ORAL Prescription
EQ 100MG BASE TABLET, CHEWABLE;ORAL Prescription

4. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

CN1861077A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Oct, 2008

(13 years ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1832949A MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN100430397C MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP1654263B1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263A1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B2 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1412357B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP1412357A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

US8414921 MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin Jul, 2028

(5 years from now)

US8414921

(Pediatric)

MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin Jan, 2029

(6 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

5. Drug name - JANUMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

CN1861077A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Oct, 2008

(13 years ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1832949A MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN100430397C MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP1654263B1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263A1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B2 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1412357B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP1412357A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

6. Drug name - JANUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

CN1861077A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Oct, 2008

(13 years ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1832949A MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN100430397C MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP1654263B1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263A1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B2 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1412357B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP1412357A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

7. Drug name - JUVISYNC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(3 years from now)

CN1861077A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Oct, 2008

(13 years ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1832949A MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN100430397C MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP1654263B1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263A1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B2 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1412357B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP1412357A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor Oct, 2026

(4 years from now)

More Information on Dosage
Strength Dosage Availability
10MG;EQ 50MG BASE TABLET;ORAL Discontinued
10MG;EQ 100MG BASE TABLET;ORAL Discontinued
20MG;EQ 50MG BASE TABLET;ORAL Discontinued
20MG;EQ 100MG BASE TABLET;ORAL Discontinued
40MG;EQ 50MG BASE TABLET;ORAL Discontinued
40MG;EQ 100MG BASE TABLET;ORAL Discontinued

8. Drug name - NOXAFIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750822 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US10117951 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US8410077 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions Mar, 2029

(6 years from now)

US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin Jun, 2031

(8 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin Jul, 2031

(8 years from now)

US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same Feb, 2033

(10 years from now)

Drugs and Companies using POSACONAZOLE ingredient

Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/16.7ML (18MG/ML) SOLUTION;INTRAVENOUS Prescription

9. Drug name - PREVYMIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 7 months from now)

US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 7 months from now)

CN100393706C MERCK SHARP DOHME Substituted Dihydroquinazolin Having Anti-Virus Capability
Apr, 2024

(1 year, 6 months from now)

CN1784390A MERCK SHARP DOHME Substituted Dihydroquinazolin Having Anti-Virus Capability
Apr, 2024

(1 year, 6 months from now)

IN200504403P1 MERCK SHARP DOHME Substituted Dihydroquinazolines
Apr, 2024

(1 year, 6 months from now)

IN230768B MERCK SHARP DOHME Substituted Dihydroquinazoline Compounds
Apr, 2024

(1 year, 6 months from now)

EP1622880B3 MERCK SHARP DOHME Substituted Dihydrochinazolines Having Antiviral Properties
Apr, 2024

(1 year, 6 months from now)

EP1622880A1 MERCK SHARP DOHME Substituted Dihydrochinazolines Having Antiviral Properties
Apr, 2024

(1 year, 6 months from now)

EP1622880B1 MERCK SHARP DOHME Substituted Dihydrochinazolines Having Antiviral Properties
Apr, 2024

(1 year, 6 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative Feb, 2033

(10 years from now)

Drugs and Companies using LETERMOVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
240MG TABLET;ORAL Prescription
480MG TABLET;ORAL Prescription

10. Drug name - SEGLUROMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439902 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Oct, 2030

(8 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Oct, 2030

(8 years from now)

Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
7.5MG;1GM TABLET;ORAL Prescription
7.5MG;500MG TABLET;ORAL Prescription

11. Drug name - STEGLATRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription

12. Drug name - STEGLUJAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(4 years from now)

US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

CN1861077A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Oct, 2008

(13 years ago)

CN1290848C MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1524082A MERCK SHARP DOHME As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prophylaxis Of Diabetes Of -Amino Tetrahydro-Imidazo (1, 2-A) Pyrazines And Triazolo [4, 2,3-A) Pyrazine
Jul, 2022

(3 months ago)

CN1832949A MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN100430397C MERCK SHARP DOHME Dipeptidyl Peptidase Iv Inhibitor Of Phosphate
Jun, 2024

(1 year, 8 months from now)

CN102149717A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199A MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN103497199B MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

CN102149717B MERCK SHARP DOHME Dioxa-Bicyclo [3.2.1]-2, 3, 4-Triol Derivatives
Aug, 2029

(6 years from now)

IN209816B MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN200400026P4 MERCK SHARP DOHME Beta-Amino Heterocyclic Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Jul, 2022

(3 months ago)

IN331468B MERCK SHARP DOHME Dioxabicyclo[ 3.2.1.]Octan E-2,3,4-Triol Derivatives,Dioxabicyclo( 3,2,1)Octan E-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP1625847B1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP2292232A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP2292232B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines For Use In The Treatment Of Diabetes Type Ii
Jul, 2022

(3 months ago)

EP1625847A1 MERCK SHARP DOHME Medical Use Of A Tetrahydrotriazolo[4,3-A]Pyrazine
Jul, 2022

(3 months ago)

EP1654263B1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263A1 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1654263B2 MERCK SHARP DOHME Phosphoric Acid Salt Of A Dipeptidyl Peptidase-Iv Inhibitor
Jun, 2024

(1 year, 8 months from now)

EP1412357B1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP1412357A1 MERCK SHARP DOHME Beta-Amino Tetrahydroimidazo(1,2-A)Pyrazines And Tetrahydrotriazolo(4,3-A)Pyrazines As Dipeptidyl Peptidase Inhibitors For The Treatment Or Prevention Of Diabetes
Aug, 2028

(5 years from now)

EP2334687B9 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687B1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

EP2334687A1 MERCK SHARP DOHME Dioxa-Bicyclo[3.2.1.]Octane-2,3,4-Triol Derivatives
Aug, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes Jan, 2023

(3 months from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Oct, 2030

(8 years from now)

US9439901 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives Oct, 2030

(8 years from now)

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 100MG BASE TABLET;ORAL Prescription
15MG;EQ 100MG BASE TABLET;ORAL Prescription

13. Drug name - TEMODAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7786118 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents Feb, 2023

(4 months from now)

US8623868 MERCK SHARP DOHME Processes of making and using pharmaceutical formulations of antineoplastic agents Feb, 2023

(4 months from now)

US6987108 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents and processes of making and using the same Sep, 2023

(10 months from now)

Drugs and Companies using TEMOZOLOMIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

14. Drug name - VERQUVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420656 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US10736896 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(10 years from now)

CN103038232A MERCK SHARP DOHME Sgc Stimulant Single Or Combined With Pde5 Inhibitor, Use Of Sgc Activators For The Treatment Of Systemic Sclerosis (Ssc)
May, 2022

(5 months ago)

CN103038232B MERCK SHARP DOHME Sgc Stimulant Single Or Combined With Pde5 Inhibitor, Use Of Sgc Activators For The Treatment Of Systemic Sclerosis (Ssc)
May, 2022

(5 months ago)

CN102939289B MERCK SHARP DOHME Substituted 5 - -1H - Pyrazolopyridine Compound And Use Thereof
May, 2031

(8 years from now)

CN102939289A MERCK SHARP DOHME Substituted 5-Fluoro-1H-Naphthyridine Compound And Application Thereof
May, 2031

(8 years from now)

CN104159898B MERCK SHARP DOHME A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound
Nov, 2032

(10 years from now)

CN105503867A MERCK SHARP DOHME Method For Preparing Substituted 5-Fluorin--1H-Pyrromonazole Series Compound
Nov, 2032

(10 years from now)

CN104159898A MERCK SHARP DOHME A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound
Nov, 2032

(10 years from now)

CN105503867B MERCK SHARP DOHME A Method Of Preparing Substituted 5-Fluoro -1H - Pyrazolopyridine Compound
Nov, 2032

(10 years from now)

IN201210257P1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines And Use Thereof
May, 2031

(8 years from now)

IN316570B MERCK SHARP DOHME Substituted 5- Fluoro-1Hpyrazolopyridines And Use Thereof
May, 2031

(8 years from now)

IN303187B MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

IN384641B MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

IN201403692P1 MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

IN201818031789A MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

EP2576548B1 MERCK SHARP DOHME The Use Of Sgc Stimulators, Sgc Activators, Alone And Combinations With Pde5 Inhibitors For The Treatment Of Systemic Sclerosis (Ssc)
May, 2031

(8 years from now)

EP2576548A1 MERCK SHARP DOHME The Use Of Sgc Stimulators, Sgc Activators, Alone And Combinations With Pde5 Inhibitors For The Treatment Of Systemic Sclerosis (Ssc)
May, 2031

(8 years from now)

EP2576547B1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines And Use Thereof
May, 2031

(8 years from now)

EP2576547A1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines And Use Thereof
May, 2031

(8 years from now)

EP3421470B1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form
Nov, 2032

(10 years from now)

EP2896617A1 MERCK SHARP DOHME Method For Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes
Nov, 2032

(10 years from now)

EP2782914B1 MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

EP3421470A1 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form
Nov, 2032

(10 years from now)

EP3421470B8 MERCK SHARP DOHME Substituted 5-Fluoro-1H-Pyrazolopyridines In Crystalline Form
Nov, 2032

(10 years from now)

EP2782914A1 MERCK SHARP DOHME Method For Producing Substituted 5-Fluoro-1H-Pyrazolopyridines
Nov, 2032

(10 years from now)

EP2896617B1 MERCK SHARP DOHME Method For Producing Substituted (Z)-Alpha-Fluoro-Beta-Amino-Acrylaldehydes
Nov, 2032

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921377 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use May, 2031

(8 years from now)

US9993476 MERCK SHARP DOHME Substituted 5-flouro-1H-pyrazolopyridines and their use May, 2031

(8 years from now)

Drugs and Companies using VERICIGUAT ingredient

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

15. Drug name - VICTRELIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(2 years from now)

CN1633446A MERCK SHARP DOHME New Peptide For As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Aug, 2010

(12 years ago)

CN102206247B MERCK SHARP DOHME A Compound Provided With Hcv Ns3/Ns4A Protease Inhibiting Activity
Aug, 2018

(4 years ago)

CN102206247A MERCK SHARP DOHME As Hepatitis C Virus Ns3 Protease Inhibitor Of Novel Peptide
Aug, 2018

(4 years ago)

IN206985B MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2021

(1 year, 2 months ago)

IN200300089P4 MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2021

(1 year, 2 months ago)

EP1481000B1 MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jan, 2023

(3 months from now)

EP1481000A2 MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jan, 2023

(3 months from now)

EP1385870A2 MERCK SHARP DOHME Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1385870B1 MERCK SHARP DOHME Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602 MERCK SHARP DOHME Administration of HCV protease inhibitors in combination with food to improve bioavailability Mar, 2027

(4 years from now)

US7772178 MERCK SHARP DOHME Pharmaceutical formulations and methods of treatment using the same Nov, 2027

(5 years from now)

Drugs and Companies using BOCEPREVIR ingredient

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
200MG CAPSULE;ORAL Discontinued

16. Drug name - WELIREG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

CN110372550B MERCK SHARP DOHME Aryl Ether And Use Thereof
Sep, 2034

(11 years from now)

CN110372550A MERCK SHARP DOHME Aryl Ether And Its Use
Sep, 2034

(11 years from now)

CN105530923B MERCK SHARP DOHME Aryl Ether And Its Use
Sep, 2034

(11 years from now)

CN105530923A MERCK SHARP DOHME Aryl Ether And Application
Sep, 2034

(11 years from now)

EP3043784A4 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3043784A1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417851B1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417852B1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417852A1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3417851A1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3043784B1 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

EP3043784B9 MERCK SHARP DOHME Aryl Ethers And Uses Thereof
Sep, 2034

(11 years from now)

Drugs and Companies using BELZUTIFAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

17. Drug name - ZEPATIER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7973040 MERCK SHARP DOHME Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Jul, 2029

(6 years from now)

US8871759 MERCK SHARP DOHME Inhibitors of hepatitis C virus replication
May, 2031

(8 years from now)

CN102159285B MERCK SHARP DOHME Quinoxaline Compound As Hcv Ns3 Macrocyclic Protease Inhibitor
Jul, 2029

(6 years from now)

CN102159285A MERCK SHARP DOHME Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors
Jul, 2029

(6 years from now)

CN102427729B MERCK SHARP DOHME Inhibitor Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

CN103880862A MERCK SHARP DOHME Inhibitor Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

CN103880862B MERCK SHARP DOHME Inhibitors Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

CN102427729A MERCK SHARP DOHME Inhibitor Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

EP2540350A1 MERCK SHARP DOHME Combinations Of A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor With Other Hcv Agents
Jul, 2029

(6 years from now)

EP2540349A1 MERCK SHARP DOHME Pharmaceutical Compositions Comprising A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor
Jul, 2029

(6 years from now)

EP2540350B1 MERCK SHARP DOHME Combinations Of A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor With Other Hcv Agents
Jul, 2029

(6 years from now)

EP2540349B1 MERCK SHARP DOHME Pharmaceutical Compositions Comprising A Macrocyclic Quinoxaline Compound Which Is An Hcv Ns3 Protease Inhibitor
Jul, 2029

(6 years from now)

EP2310095B1 MERCK SHARP DOHME Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors
Jul, 2029

(6 years from now)

EP2310095A1 MERCK SHARP DOHME Macrocyclic Quinoxaline Compounds As Hcv Ns3 Protease Inhibitors
Jul, 2029

(6 years from now)

EP2410844B1 MERCK SHARP DOHME Inhibitors Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

EP2410844A4 MERCK SHARP DOHME Inhibitors Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

EP2410844A1 MERCK SHARP DOHME Inhibitors Of Hepatitis C Virus Replication
Mar, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;100MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.